{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:35:46Z","timestamp":1707525346106},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,26]]},"DOI":"10.7759\/cureus.47727","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:15:59Z","timestamp":1698333359000},"source":"Crossref","is-referenced-by-count":0,"title":["Recurrent Pericardial Effusion in a Patient With Delayed Progression of Melanoma Treated With Immune Checkpoint Inhibitors"],"prefix":"10.7759","author":[{"given":"Elsie A","family":"Valencia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Anumolu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinky","family":"Jha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2015.1093418","article-title":"Nivolumab in combination with ipilimumab for the treatment of melanoma","volume":"15","author":"Somasundaram R","year":"2015","unstructured":"Somasundaram R, Herlyn M. Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Rev Anticancer Ther. 2015, 15:1135-41. 10.1586\/14737140.2015.1093418","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi AR","year":"2020","unstructured":"Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol. 2020, 10:91. 10.3389\/fonc.2020.00091","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205218","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review","volume":"13","author":"Shalata W","year":"2021","unstructured":"Shalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha I, Yakobson A. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Cancers (Basel). 2021, 13:5218. 10.3390\/cancers13205218","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/HPC.0000000000000327","article-title":"Cardiovascular toxicity associated with immune checkpoint inhibitor therapy: a comprehensive review","volume":"22","author":"Chitsazan M","year":"2023","unstructured":"Chitsazan M, Amin A, Ladel L, Baig A, Chitsazan M. Cardiovascular toxicity associated with immune checkpoint inhibitor therapy: a comprehensive review. Crit Pathw Cardiol. 2023, 22:69-82. 10.1097\/HPC.0000000000000327","journal-title":"Crit Pathw Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong J","year":"2021","unstructured":"Gong J, Drobni ZD, Zafar A, et al.. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:e002771. 10.1136\/jitc-2021-002771","journal-title":"J Immunother Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/794842","article-title":"Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication","volume":"2015","author":"Yun S","year":"2015","unstructured":"Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015, 2015:794842. 10.1155\/2015\/794842","journal-title":"Case Rep Oncol Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.08.023","article-title":"Pericardial effusion with tamponade physiology induced by nivolumab","volume":"222","author":"Nesfeder J","year":"2016","unstructured":"Nesfeder J, Elsensohn AN, Thind M, Lennon J, Domsky S. Pericardial effusion with tamponade physiology induced by nivolumab. Int J Cardiol. 2016, 222:613-4. 10.1016\/j.ijcard.2016.08.023","journal-title":"Int J Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000447053","article-title":"Nivolumab-induced pericardial tamponade: a case report and discussion","volume":"136","author":"Kushnir I","year":"2017","unstructured":"Kushnir I, Wolf I. Nivolumab-induced pericardial tamponade: a case report and discussion. Cardiology. 2017, 136:49-51. 10.1159\/000447053","journal-title":"Cardiology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000217","article-title":"Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy","volume":"41","author":"de Almeida DV","year":"2018","unstructured":"de Almeida DV, Gomes JR, Haddad FJ, Buzaid AC. Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy. J Immunother. 2018, 41:329-31. 10.1097\/CJI.0000000000000217","journal-title":"J Immunother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4236\/jct.2018.912085","article-title":"Pericardial effusion with tamponade, an immune-related adverse event associated with nivolumab therapy: a case report and review of the literature","volume":"9","author":"Naime F","year":"2019","unstructured":"Naime F. Pericardial effusion with tamponade, an immune-related adverse event associated with nivolumab therapy: a case report and review of the literature. J Cancer Ther. 2019, 9:10.4236\/jct.2018.912085","journal-title":"J Cancer Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0104-y","article-title":"Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature","volume":"7","author":"Shaheen S","year":"2018","unstructured":"Shaheen S, Mirshahidi H, Nagaraj G, Hsueh CT. Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Exp Hematol Oncol. 2018, 7:11. 10.1186\/s40164-018-0104-y","journal-title":"Exp Hematol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.026","article-title":"Immune checkpoint inhibitor-associated pericarditis","volume":"14","author":"Altan M","year":"2019","unstructured":"Altan M, Toki MI, Gettinger SN, et al.. Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol. 2019, 14:1102-8. 10.1016\/j.jtho.2019.02.026","journal-title":"J Thorac Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0760-4","article-title":"Pericardial effusion under nivolumab: case-reports and review of the literature","volume":"7","author":"Saade A","year":"2019","unstructured":"Saade A, Mansuet-Lupo A, Arrondeau J, et al.. Pericardial effusion under nivolumab: case-reports and review of the literature. J Immunother Cancer. 2019, 7:266. 10.1186\/s40425-019-0760-4","journal-title":"J Immunother Cancer"},{"key":"ref14","article-title":"How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy","volume":"9","author":"Ma Y","year":"2019","unstructured":"Ma Y, Wang Q, Dong Q, Zhan L, Zhang J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019, 9:1546-53.","journal-title":"Am J Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100156","article-title":"Progressive pleural effusion as an immune-related adverse event in NSCLC: a case report","volume":"2","author":"Shen CI","year":"2021","unstructured":"Shen CI, Yeh YC, Chiu CH. Progressive pleural effusion as an immune-related adverse event in NSCLC: a case report. JTO Clin Res Rep. 2021, 2:100156. 10.1016\/j.jtocrr.2021.100156","journal-title":"JTO Clin Res Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133207","article-title":"Imaging assessment of toxicity related to immune checkpoint inhibitors","volume":"14","author":"Berz AM","year":"2023","unstructured":"Berz AM, Boughdad S, Vietti-Violi N, Digklia A, Dromain C, Dunet V, Duran R. Imaging assessment of toxicity related to immune checkpoint inhibitors. Front Immunol. 2023, 14:1133207. 10.3389\/fimmu.2023.1133207","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00580-9","article-title":"Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors","volume":"23","author":"M\u00f6nch S","year":"2023","unstructured":"M\u00f6nch S, Heimer MM, Winkelmann M, et al.. Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors. Cancer Imaging. 2023, 23:58. 10.1186\/s40644-023-00580-9","journal-title":"Cancer Imaging"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/192052-recurrent-pericardial-effusion-in-a-patient-with-delayed-progression-of-melanoma-treated-with-immune-checkpoint-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:58Z","timestamp":1707509278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/192052-recurrent-pericardial-effusion-in-a-patient-with-delayed-progression-of-melanoma-treated-with-immune-checkpoint-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.47727","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}